Genetic counseling and testing for susceptibility to breast and/or ovarian cancer vis-à-vis
BRCA1 and
BRCA2 (
BRCA1/2) testing is now widely available to women and men with suggestive personal and family histories of these cancers. To date, over 250,000 individuals have undergone predictive testing for hereditary cancer risk, most frequently for
BRCA1/2 mutations [
1]. Mutations in these genes are associated with lifetime breast cancer risks of up to 75% and ovarian cancer risks up to 51% [
2]. Given these risks, it is recommended that, by age 25, mutation carriers undergo heightened surveillance for breast cancer; in addition, options for chemoprevention and risk-reducing mastectomy should be considered [
3]. Risk-reducing oophorectomy by age 35–40 is also recommended given the lack of effective screening for ovarian cancer [
3].
Because of the substantial medical implications associated with
BRCA1/2 mutations, carriers are advised to inform adult relatives of their possible risk status. Consistent with autosomal dominant inheritance, this risk is 50% in first-degree relatives. Indeed, a major reason why some individuals seek testing is to learn whether hereditary risk may be passed on to others in the family, especially children [
4–
6]. However, the social and behavioral impact of the knowledge of a mother’s
BRCA1/2 test result on her at-risk children’s psychosocial and developmental functioning has not been well studied. Among fathers who seek
BRCA1/2 testing, even less is known about the effect of disclosure among minor-age children, although men who pursue such information may do so when their children are at or approaching adulthood [
4].
Past works indicate that among mothers who undergo
BRCA1/2 testing, the rate of disclosure to children is about 50%, and may be associated with the age of the child (older versus younger) and the presence of a more open parent-child communication style [
7–
9]. In mothers who have had early-onset breast cancer, regardless of whether the family history was consistent with hereditary breast cancer, Miesfeldt and colleagues reported 81% were concerned about their children’s breast cancer risk, and 71% felt childhood was the most appropriate time in life to begin providing education about hereditary cancer [
10]. A majority of mothers believed that parents play an important role in providing such education and many also wanted professional guidance in doing so. That desire is understandable in light of work demonstrating that the decision to disclose results may be associated with elevated distress in mothers [
8,
9]. However, in children, disclosure does not appear to be associated with negative outcome [
11,
12], although daughters of mothers with breast cancer may be prone to significant worry about their health and genetic risk, and may be especially susceptible to distress during the genetic testing process itself [
13,
14]. This literature is also small, and therefore may not fully capture the range and type of concern held by parents and their children. Not surprisingly, notification of their mother’s positive
BRCA1/2 status may result in heightened interest in genetic testing and proactive adoption of lifestyle changes [
11]; this is true despite the fact that testing of minors is uniformly discouraged by medical professionals owing to the lack of medical benefit and concerns about autonomous decision making and children’s psychological well-being in this circumstance [
15,
16].
Given the aforementioned issues, there has been increasing attention to the phases of decision making and disclosure of
BRCA1/2 test results between parents and children, including how parents navigate issues of if, when, and how to disclose to children, and how to appropriately handle their own and their children’s responses to these discussions [
17]. Although it is recommended that discussions about family communication be included in cancer genetic counseling sessions [
18,
19], physicians and genetic counselors may have little involvement in assisting parents with decisions regarding communication of test results to minor children specifically [
7]. Lack of such discussion by health professionals may be due, in part, to parents not seeking advice--turning to family members instead [
7]. Indeed, mothers (especially those with higher decisional conflict about whether or not to discuss their
BRCA1/2 result with children) have indicated a strong desire to receive additional resources to assist in this process, including literature, access to prior testing participants who faced the same situation, support groups, and other forms of normative guidance [
20].
To fill this gap, we conducted formative research to further inform the development of a decision support intervention--specifically, a decision aid--to assist mothers undergoing BRCA1/2 testing with their choices about whether, when, and how to discuss their cancer genetic test results with their children, and to help them anticipate their and their children’s needs and responses related to this decision. Our decision aid is designed to be shared with mothers after their initial genetic counseling session, but prior to when they receive their test results. The decision aid is currently being evaluated in a randomized controlled trial to determine whether communication and related outcomes among genetic testing participants are improved by providing a decision support intervention in addition to standard pre- and posttest genetic counseling.
The purpose of the current paper is to highlight the conceptual frameworks that informed the development of the intervention. In addition, we provide an overview of the formative research process used to develop its content and other specific aspects of the decision aid. Finally, we conclude with a discussion of directions for future research and evaluation efforts in this area.